Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Reich

Showing results (201-210 of 217) with videos related to

Pageof 22
Sort By:
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 7, 2018
S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 2 - Besondere Patientengruppen und spezielle BehandlungssituationenAlexander Nast, Lasse Amelunxen, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 7, 2018
S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situationsAlexander Nast, Lasse Amelunxen, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 12, 2018
S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatmentAlexander Nast, Lasse Amelunxen, Matthias Augustin, et al.
JAMA Dermatology|July 31, 2024
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical TrialKilian Eyerich, Khusru Asadullah, Andreas Pinter, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 6, 2012
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). UpdateAlexander Nast, Wolf-Henning Boehncke, Ulrich Mrowietz, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2011
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseMarcus Maurer, Sabine Altrichter, Thomas Bieber, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
Contact Dermatitis|July 1, 2016
A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patientsGötz A Westphal, Hans-Peter Rihs, Antje Schaffranek, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 11, 2007
Evidence-based (S3) guidelines for the treatment of psoriasis vulgarisAlexander Nast, Ina B Kopp, Matthias Augustin, et al.
Pageof 22

Showing results (201-210 of 217) with videos related to

Sort By:
Pageof 22
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 7, 2018
S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 2 - Besondere Patientengruppen und spezielle BehandlungssituationenAlexander Nast, Lasse Amelunxen, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 7, 2018
S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situationsAlexander Nast, Lasse Amelunxen, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 12, 2018
S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatmentAlexander Nast, Lasse Amelunxen, Matthias Augustin, et al.
JAMA Dermatology|July 31, 2024
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical TrialKilian Eyerich, Khusru Asadullah, Andreas Pinter, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 6, 2012
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). UpdateAlexander Nast, Wolf-Henning Boehncke, Ulrich Mrowietz, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2011
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseMarcus Maurer, Sabine Altrichter, Thomas Bieber, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
Contact Dermatitis|July 1, 2016
A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patientsGötz A Westphal, Hans-Peter Rihs, Antje Schaffranek, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 11, 2007
Evidence-based (S3) guidelines for the treatment of psoriasis vulgarisAlexander Nast, Ina B Kopp, Matthias Augustin, et al.
Pageof 22